Диссертация (1154359), страница 39
Текст из файла (страница 39)
Inmam,N.S.B. Rawson, L.V. Wilton. – 1985. - 213 p.424.Inman, W.H.W. Requirements for risk benefit assessment of drugsbefore withdrawal / W.H.W. Inmam // B.I.R.A. J. – 1986. – Vol. 5 (2). – P.11-15.425.Innocenti, F. Pharmacogenomics: Methods and Protocols (Meth-ods in Molecular Biology) / F. Innocenti // Humana Press. – 2005.
- 224 p.426.Interaction of ACE genotype and salt intake on hypertension amongChinese Kazakhs: results from apopulation-based cross-sectional study /Y. Wang, B. Zhang, L. Hou [et al.] // BMJ Open. – 2017. – Vol.17;7(5):e014246. doi: 10.1136/bmjopen-2016-014246.427.International comparison of comparative effectiveness research infive jurisdictions: insights for the US / A.R. Levy, C. Mitton, K.M. Johnston [et al.] // Pharmacoeconomics.
– 2010. – Vol. 28. – P. 813-830.250428.Interpreting indirect-treatment comparisons and network meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices - part 1 / J.P. Jansen, R. Fleurence, B.Devine [et al.] // Value Health. – 2011. – Vol. 14.
– P. 429-437.429.Jackevicius, C. Adherence with statin therapy in elderly patients withand without acute coronary syndromes / C. Jackevicius, M. Mamdani, J.Tu // JAMA. – 2002. – Vol. 288. – P. 462–467.430.Jonson, K. Canadian Hypertension Education Program. The 2007Canadian Hypertension Education Program recommendations: the scientific summary – an annual update / K. Jonson // Can. J.
Cardiol. – 2007. Vol.23, N. 7. - P. 521-527.431.Jonsson, E. Health technology assessment and screening in Sweden /E. Jonsson, D. Banta, T. Scherstén // International Journal of TechnologyAssessment in Health Care. – 2001. – Vol. 17. – P. 380–388.432.Jonsson, E. Management of health technologies: an internationalview / E. Jonsson, H.D. Banta // BMJ. – 1999. – Vol. 319. – P. 1293.433.Jonsson, E. Report of the survey results “Educational/training activi-ties in INAHTA agencies” / E.
Jonsson, J.Chamova // Stockholm,INAHTA, 2000 (www.inahta.org).434.Jun-Feng Su, Xiao-Hui Hu, Cheng-Yan Li.Risk factors forclopidogrel resistance in patients with ischemic cerebral infarction and thecorrelation with ABCB1 gene rs1045642 polymorphism. // Experimentaland Therapeutic Medicine. 2015. -№9. – P. 267-271.435.Kaesbach, W. Pharmaceutical policies in Germany and Europeancompetition law / W. Kaesbach // Eurohealth. – 2002. - Vol.8, N. 2. – P.12 – 13.436.Kardas, P.J. Patient compliance with antibiotic treatment for respira-tory tract infections / P.J.
Kardas // J. Antimicrob. Chemother. - 2002. - 49.– P. 897-903.251437.Katoh, M. Inhibitory potencies of 1,4 dihydropyridine calcium an-tagonists to P- glycoprotein- mediated transport: comparison with the effects on CYP3A4/M. Katoh, M. Nakajima[et al.] //Pharm Res. – 2000. Vol.17, N. 10.
– P. 1189-1197.438.Karaźniewicz-Łada M., Danielak D., Rubiś B., Burchardt P.,Komosa A, Lesiak M, Główka F. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and itsmetabolites. // J Clin Pharm Ther. 2015. - №40(2)- P. 226-257.439.Khokhlov A. The Prevalence of eNOS and AGTR2 Gene Polymor-phism In Patient With Coronary Artery Disease / A. Khokhlov, A.Miroshnikov, N. Pozdnyakov, D. Komarov. // Clinical Therapeutics. –2015.
- Volume 37, Issue 8, Supplement. - p. 69.440.Kubota, K. Prescription-event monitoring in Japan (J-PEM) / K.Kubota // Drug Saf. – 2002. – Vol. 25(6). – P. 441-444.441.Lack of association of CYP11B2-344C/T polymorphism with essen-tial hypertension: a meta-analysis / J-F Chen, J Jing, H Tan [et al.] // International Journal of Clinical and Experimental Medicine.
– 2015. –Vol.8(6). – P. 9162-9167.442.Lammers, P., et al., Barriers to the Use of Trastuzumab for HER2+Breast Cancer and thePotential Impact of Biosimilars: A Physician Surveyin the United States and Emerging Markets. Pharmaceuticals, 2014. 7(9):p. 943-953.443.Lazarou, J. Incidence of adverse drug reactions in hospitalized pa-tients / J. Lazarou,B.N.
Pomeranz, P.N. Corey // JAMA. – 1998. – Vol.279. – P. 1200–1205.252444.Leape, L.L. The nature of adverse events in hospitalized patients.Results of the Harvard Medical Practice Study II, N. / L.L. Leape, T.A.Brennan , N. Laird // Engl. J. Med. – 1991. – Vol. 324. – P. 377-384.445.Lee, H., Is extrapolation of the safety and efficacy data in one indica-tion to another appropriate for biosimilars? The AAPS journal, 2014.16(1): p. 22-28.446.Lehmann, E.D. Multiple definitions of «compliance» / E.D. Leh-mann, K.D. Hopkins, R.G. Gosling // Clinical Science. - 1996.
– Vol. 90.- P. 433-435.447.Lepori, V. Adverse internal medicine drug effects at hospital admis-sion / V.Lepori, A. Perren, C. Marone // Schweiz Med Wochenschr. –1999. – Vol. 19, 129 (24). – P. 915-922.448.Levy, G. Developing compliance instructions for drug labeling / G.Levy, M.K. Zamacona, W.J. Jusko // Clin. Pharmacol. Ther. - 2000. – Vol.68.
- P. 586-591.449.Liao, X. Association of alpha-ADD1 Gene and Hypertension Risk: AMeta-Analysis / X. Liao, W. Wang, Z. Zeng [et al.] // Medical ScienceMonitor : International Medical Journal of Experimental and Clinical Research. – 2015. – Vol.21. – P. 1634-1641. doi:10.12659/MSM.893191.450.Lindquist R., Gersema L.M. Understanding and preventing adversedrug events / R.
Lindquist, L.M. Gersema // AACN Clin. – 1998. – Vol.9(1). – P. 119-128.451.Liu, H. A comparison study of multiple measures of adherence toHIV protease inhibitors / H. Liu // Ann Intern Med. – 2011. – Vol.134(10). – P. 968–977.452.Louis, P.C.A. Recherches sur les effets de la saignee dans quelquesmaladies inflammatoires / P.C.A. Loui. – Paris, 1835.253453.Maher, K. Disease progression, adherence and response to proteaseinhibitor therapy for HIV infection in an Urban Veterans Affairs MedicalCenter / K.
Maher // J Acquir Immune Defic Syndr. – 1999. – Vol. 22(4).– P. 358–363.454.Mancia, G. Fagard R. et al. 2013 ESH/ESC Guidelines for the man-agement of arterial hypertension: The Task Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) andof the European Society of Cardiology (ESC). J Hypertension 2013; 31:1281–1357.455.Matsui S. Genomic Biomarkers for Personalized Medicine: Devel-opment and Validation in Clinical Studies//Computational and Mathematical Methods in Medicine. -2013; 2013:865980.
Epub 2013 Apr 17 DOI:10.1155/2013/865980.456.McKeage, K., A review of CT-P13: an infliximab biosimilar.BioDrugs : clinicalimmunotherapeutics, biopharmaceuticals and genetherapy, 2014. 28(3): p. 313-321.457.Medical Research Council // Brit. Med. J. – 1948. – Vol. 2.
– P.769–782.458.Medication Errors at the Administration Stage in an Intensive CareUnit / E. Tissot, C. Cornette, P. Demoly[at al.] // Intensive Care. Med. –1999. – Vol. 25(4). – P. 353-359.459.Medication errors in a pediatric department / P.M. Olsen, H.Lorentzen, K. Thomsen [at al.] // Ugeskr Laeger. – 1997. – Vol.
14,159(16). – P. 2392-2395.460.Medication nonadherence is associated with a broad range of adverseoutcomes in patients with coronary artery disease /P. Ho, D. Magid, S.Shetterly [et al.] // Am. Heart J. – 2008. – Vol. 155. – P. 772–779.254461.Meltzer, D. Inconsistencies in the “societal perspective” on cost ofthe Panel on Cost-Effectiveness in Health and Medicine / D.
Meltzer D.,M. Johanennesson M // Med. Decis. Making. - 1999. - Vol. 19. - P. 371–378.462.Michallet, M., et al., BiOsimilaRs in the management of anaemiasecondary to chemotherapy in HaEmatology and Oncology: results of theORHEO observational study. BMC cancer, 2014. №14. - p. 503.463.Morin, S. is diclophenac a valuable CYP2C9 probe in humans?/S.Morin, M. Loriot [et al.] // Eur JClin Pharmacology.- 2001.- Vol. 56(11). - P. 793–800.464.Mocharra M., et all on behalf of Work Package 8, European Networkfor Health Technology Assessment and Research (EUnetHTA project).Survey report on HTA organizations. Barcelona, Spain: Catalan Agencyfor Health Technology Assessment and Research.
Catalan Health Service.Department of Health. - Autonomous Government of Catalonia; May2008.European network for Health Technology Assessment: JA2 20122015 |-www.eunethta465.Morbach C, Wagner M, Güntner S, et al. Heart failure in patientswith coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort / C.Morbach, M. Wagner, S. Güntner [et al.] // BMC Cardiovascular Disorders. – 2017. – Vol.17. – P.108. doi:10.1186/s12872-017-0543-0.466.Morse B.L, Kim R.B.Is personalized medicine a dream or a reality?// Crit Rev Clin Lab Sci.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
